Immune function

Outcome · 5 studies in the Atlas

Function of the immune system, especially vaccine response; improved by low-dose everolimus in older adults.

Evidence at a glance

Tier	What it means	Studies
A	Systematic review of human data	1
B	Direct human evidence	4

Studies

Study	Year	Tier	Finding
LEE2024	2024	A	The first systematic review of rapamycin/rapalogs in humans for aging. Screened 18,400 articles, included 19 studies. Found improvements in immune, cardiovascular, and skin (integumentary) parameters;
MAN2021	2021	B	The crucial reality check. After the promising phase 2a, the large phase 3 trial (n=1024) FAILED its primary endpoint - RTB101 did not reduce clinically symptomatic respiratory illness (26% vs 25%, p=
KRA2018	2018	B	A safety-first pilot RCT (n=25, ages 70-95) asking the basic question before any longevity trial: is daily rapamycin safe in healthy older people? Over 8+ weeks it was well tolerated with only minor r
MAN2018	2018	B	The strongest human evidence that mTOR inhibition can rejuvenate a specific function of aging - immunity. In 264 elderly people, a low-dose combination that selectively hits TORC1 significantly reduce
MAN2014	2014	B	Low-dose everolimus improved influenza vaccine response by ~20% and reduced PD-1 expression on T lymphocytes.

Related entities

Open in the Atlas explorer